<DOC>
	<DOCNO>NCT02815059</DOCNO>
	<brief_summary>This Phase I , single-center , open label , prospective , single-arm , dose-escalation multi-dose study evaluate use ibrutinib combination dasatinib prednisone therapy .</brief_summary>
	<brief_title>Study Pts With Philadelphia Chromosome-Pos ALL With Comb Ibrutinib , Dasatinib , Prednisone</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Confirmed new diagnosis Philadelphia chromosomepositive BCRABL1 positive precursor B cell acute lymphoblastic leukemia ( BALL ) base ≥ 20 % lymphoblasts bone marrow blood . Outside specimen subject central review HCI ( Huntsman Cancer Institute ) Department Pathology . BCRABL1 Philadelphiachromosome positivity may determine RTPCR , conventional cytogenetics and/or FISH . Men woman ≥ 50 year age ECOG status 0 2 Biochemical value define protocol . Women childbearing potential men sexually active must practice highly effective method birth control study consistent local regulation regard use birth control method subject participate clinical trial . Men must agree donate sperm study . For woman , restriction apply 1 month last dose study drug . For men , restriction apply 3 month last dose study drug . Women childbearing potential must negative serum ( betahuman chorionic gonadotropin [ βhCG ] ) urine pregnancy test screening within 7 day enrollment . Able provide inform consent willing sign approve consent form conform federal institutional guideline . Major surgery wound fully heal within 4 week enrollment . Prior exposure dasatinib ( &gt; 7 day ) , Bruton 's tyrosine kinase inhibitor exposure , prior chemotherapy ALL ( 7 day steroid allow ) History stroke intracranial hemorrhage within 6 month prior enrollment . Grade ≥ 2 QTc prolongation screen ECG within 28 day enrollment , history ventricular arrhythmia . Clinically significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 ( moderate ) Class 4 ( severe ) cardiac disease define New York Heart Association Functional Classification . Hepatic impairment ( Child Pugh Classes A C ) consider result leukemic involvement determine PI Requires anticoagulation warfarin equivalent vitamin K antagonist ( eg , phenprocoumon ) . Requires chronic treatment strong CYP3A inhibitor . Vaccinated live , attenuated vaccine within 4 week enrollment . Known history human immunodeficiency virus ( HIV ) active Hepatitis C Virus active Hepatitis B Virus infection uncontrolled active systemic infection . Women pregnant breastfeeding . Herbal preparation overthecounter supplement contain herbal ingredient ( St. John 's Wort , Estroven , Blue Cohosh ) prohibit treatment must stop within 24h first dose ibrutinib . Any lifethreatening illness , medical condition , organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism ibrutinib capsule , put study outcome undue risk . Known central nervous system lymphoma ( include diagnosis ALL CNS involvement )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>